Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

* Patients who have previously received irinotecan and temozolomide in combination without progressive disease while on therapy are eligible

Adequate Bone Marrow Function Defined as:

For patients with solid tumors without known bone marrow involvement (no older than 7 days at the start of therapy):

* Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3

* Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

* Hemoglobin \>= 8.0 g/dl at baseline (may receive red blood cell \[RBC\] transfusions)

Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows (no older than 7 days at the start of therapy):

* Age: maximum serum creatinine (mg/dL)

* 1 to \< 2 years: 0.6 (male and female)

* 2 to \< 6 years: 0.8 (male and female)

* 6 to \< 10 years: 1 (male and female)

* 10 to \< 13 years: 1.2 (male and female)

* 13 to \< 16 years: 1.5 (male), 1.4 (female)

* \>= 16 years: 1.7 (male), 1.4 (female)

Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age (no older than 7 days at the start of therapy)

Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN = 135 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L (no older than 7 days at the start of therapy)

Serum albumin \>= 2 g/dL (no older than 7 days at the start of therapy)

Pulse oximetry \> 94% on room air if there is clinical indication for determination (e.g. dyspnea at rest)

Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled

Nervous system disorders (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0) resulting from prior therapy must be =\< grade 2 with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible

Serum triglyceride level =\< 300 mg/dL (no older than 7 days at the start of therapy)

Serum total cholesterol level =\< 300 mg/dL (no older than 7 days at the start of therapy)

Random or fasting blood glucose =\< the upper normal limits for age; if the initial blood glucose is a random sample that is outside of the normal limits, then follow-up fasting blood glucose can be obtained and must be =\< the upper normal limits for age (no older than 7 days at the start of therapy)

International normalized ratio (INR) =\< 1.5 (no older than 7 days at the start of therapy)

Not currently receiving anticoagulation therapy

All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines

Tissue blocks or slides must be sent for all patients; if tissue blocks or slides are unavailable, the study chair must be notified prior to enrollment

Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 6 months after participation in this study; abstinence is an acceptable method of contraception

Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid

Patients must not have received enzyme-inducing anticonvulsants for at least 7 days prior to enrollment

Patients must not be receiving any strong CYP3A4 or P-glycoprotein (P-gp) inducers or inhibitors within 7 days prior to enrollment; moderate inducers or inhibitors of CYP3A4 and P-gp should also be avoided during ABI-009 treatment, if possible

* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment

* Subcutaneous port placement or central line placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment

* Core biopsy within 7 days prior to enrollment

* Fine needle aspirate within 7 days prior to enrollment

* NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy

What this study is about